ALOCRIL
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALOCRIL is an ophthalmic solution approved in 1999 for eye-related indications, delivered as topical drops. The exact mechanism of action and indication are not fully specified in available data, but the product is a small-molecule therapeutic delivered via ocular route.
LOE Approaching
Product is approaching loss of exclusivity with modest competitive pressure (30/100), signaling potential downsizing or transition planning for commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALOCRIL positions offer limited growth opportunity given LOE approaching status and zero linked job postings. Career roles would focus on managing declining revenue, optimizing cost structures, and executing transition strategies as generic competition emerges.
Brand ManagerField Sales Representative
Worked on ALOCRIL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.